Sanofi shares are trading higher after the company and Teva reported Phase 2b data showing duvakitug maintained efficacy through 44 weeks in ulcerative colitis and Crohn's disease. Separately, Sanofi announced an mRNA therapeutics collaboration with ScionxBio.